Ixekizumab - Eli Lilly

Drug Profile

Ixekizumab - Eli Lilly

Alternative Names: LY-2439821; Taltz

Latest Information Update: 05 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Oregon Health & Science University
  • Class Antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Erythrodermic psoriasis; Pustular psoriasis
  • Phase III Ankylosing spondylitis; Spondylarthritis
  • Phase II Bullous pemphigoid; Pityriasis rubra pilaris; Rheumatoid arthritis

Most Recent Events

  • 24 Jul 2018 Eli Lilly plans to submit NDA to USFDA for ankylosing spondylitis in late 2018
  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2018 Registered for Psoriatic arthritis (Treatment-experienced) in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top